Additionally, Amentoflavon treatment decreased Erk/NF-κB activation and expression of tumor progression-related proteins in U-2 OS osteosarcoma cell xenograft models when compared to solvent-treated groups. This evidence concerns the gene NFKB1 and neoplasm.